Is MACROGENICS INC (MGNX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 26.6% / 30% | 143.0% / 30% | 3.1% / 30% | 6.35% / 5% | ✗ NOT HALAL |
| DJIM | 26.6% / 33% | 143.0% / 33% | 3.1% / 33% | 6.35% / 5% | ✗ NOT HALAL |
| MSCI | 14.3% / 33% | 77.1% / 33% | 1.6% / 33% | 6.35% / 5% | ✗ NOT HALAL |
| S&P | 26.6% / 33% | 143.0% / 33% | 3.1% / 33% | 6.35% / 5% | ✗ NOT HALAL |
| FTSE | 14.3% / 33% | 77.1% / 33% | 1.6% / 50% | 6.35% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -22.5% | |
| Operating Margin | -29.3% | |
| Net Margin | -49.9% | |
| Return on Equity (ROE) | -86.9% | |
| Return on Assets (ROA) | -17.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$81M |
| Free Cash Flow | -$83M |
| Total Debt | $37M |
| Debt-to-Equity | 66.1 |
| Current Ratio | 5.1 |
| Total Assets | $257M |
Price & Trading
| Last Close | $3.18 |
| 50-Day MA | $2.17 |
| 200-Day MA | $1.73 |
| Avg Volume | 1.1M |
| Beta | 1.4 |
|
52-Week Range
$0.99
| |
About MACROGENICS INC (MGNX)
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MACROGENICS INC (MGNX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MACROGENICS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MACROGENICS INC's debt ratio?
MACROGENICS INC's debt ratio is 26.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 14.3%.
What are MACROGENICS INC's key financial metrics?
MACROGENICS INC has a market capitalization of $186M, and revenue of $150M. The company maintains a gross margin of -22.5% and a net margin of -49.9%. Return on equity stands at -86.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.